Some patients with rectal cancer who experience complete clinical response after neoadjuvant therapy may safely avoid total mesorectal excision.
Instead of analyzing adverse events (AEs) in the traditional fashion, we ought to consider alternatives in this new era of personalized medicine.
Gastrointestinal Cancers News
Recent research has indicated the potential for IL-12 therapy to be effective in combination with new and emerging biologics including other immunomodulatory drugs.
More Gastrointestinal Cancers Information
A fact sheet to review the different types of test used to detect colon cancer and polyps.
This fact sheet helps patients with metastatic colorectal cancer to learn more about personalized medicine and KRAS gene testing.
This fact sheet explains the importance of screening for colorectal/rectal/bowel cancer causes, symptoms, and risk factors.
This patient fact sheet explains two tests used in an approach called "personalized medicine."
This fact sheet offers tips for coping with colorectal cancer, diagnosis, treatment, and symptoms.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Statistical Significance, Uncertainty, and KEYNOTE-010
- Chlorhexidine Dressing Reduces May Reduce Incidence of Catheter-related Bloodstream Infections
- Gene-expression Prognostic Signatures Guide Adjuvant Chemotherapy of Early-stage Breast Cancer
- PD-1 and Checkpoint Inhibitors May Benefit Some Patients With SCLC
- Carfilzomib Efficacious Against Multiple Myeloma Regardless of Cytogenetic Abnormalities
- Breast Cancer (Invasive) Treatment Regimens
- Breast Cancer (Recurrent or Metastatic) Treatment Regimens
- TRUS-biopsy Poorly Detects Prostate Cancer
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Mental Disorder Risk High Among Patients With Cancer During Treatment and Before Diagnosis
- The Future of the Biomedical Research Workforce in the United States
- Dosage Adjustment to Increase Plasma Trough Levels Requires Investigation for Treatment of RCC and Sarcoma
- VSIG10L Gene May Signify Susceptibility to Esophageal Adenocarcinoma
- Researchers Identify the "Cell of Origin" in Basal Cell Carcinoma
- Half of Patients in Remission 11 Months After Nilotinib Discontinuation